Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 22, Issue 3, 2010, Pages 971-980

  Haldenwanger, Andreas ^a   Eling, Paul ^c   Kastrup, Andreas ^a,d   Hildebrandt, Helmut ^b,d  

^a UNIVERSITY OF BREMEN   (Germany)

^b UNIVERSITY OF OLDENBURG   (Germany)

^c RADBOUD UNIVERSITY   (Netherlands)

^d Municipal Hospital of Bremen   (Germany)

Author keywords

Alzheimer's disease; cognitive speed; MCI; memory; total tau

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN;

AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COGNITION; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE COURSE; EDUCATIONAL STATUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MENTAL PERFORMANCE; MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL;

EID: 78650668064     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101203     Document Type: Article

References (52)

1. Hardy J, Duff K, Hardy KG, Perez-Tur J, Hutton M (1998) Genetic dissection of Alzheimer's disease and related dementias: amyloid and its relationship to tau. NatNeurosci 1, 355-358.
2. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
3. Naslund J, Haroutunian V, Mohs R, Davis P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283, 1571-1577.
4. Crystal H, Dickson D, Fuld P, Masur D, Scott R, Mehler M, Masdeu J, Kawas C, Aronson M, Wolfson L (1988) Clinico- pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology 38, 1682-1687.
5. Ingelsson M, Fukumoto, H, Newell KL Growdon JH, Hedley- Whyte ET, Frosch MP, Albert MS, Hyman BT, Irizarry MC (2004) Early A/3 accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62, 925931.
6. Jack CR, Knopman DS, Jagust WJ, Leslie MS, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkes of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128.
7. Lowndes G, Savaqge G (2007) Early detection of memory impairment in Alzheimer's disease: aneurocognitive perspective on assessment. Neuropsychol Rev 17, 193-202.
8. Mickes L, Wixted JT, Fennema-Notestine C, Galasko D, Bondi MW, Thal LJ, Salmon DP (2007) Progressive impairment on neuropsychological tasks in a longitudinal study of preclinical Alzheimer's disease. Neuropsychology 21, 696-705.
9. Lambon Ralph MA, Patterson K, Graham N, Dawson K, Hodges JR (2003) Homogeneity and heterogeneity in mild cognitive impairment and Alzheimer's disease: a cross- sectional and longitudinal study of 55 cases. Brain 126, 23502362.
10. Hutchinson AD, Mathias JL (2007) Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: A meta-analytic review. J Neurol Neurosurg Psychiatry 78, 917-928.
11. Reed BR, Mungas DM, Kramer JH, Ellis W, Vinters HV, Zarow C, Jagust WJ, Chui HC (2007) Profiles of neuropsy- chological impairment in autopsy-defined Alzheimer's disease and cerebro-vascular disease. Brain 130, 731-739.
12. Busse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC (2003) Subclassifications for mild cognitive impairment. Psychol Med 33, 1029-1038.
13. De Jager CA, Hogervorst E, Combrinck M, Budge MM (2003) Sensitivity and specificity of neuropsychological tests for mild cognitive impairment, vascular cognitive impairment and Alzheimer's disease. Psychol Med 33, 1039-1050.
14. Mariani E, Monastero R, Mecocci P (2007) Mild cognitive impairment: a systematic review. JAlzheimers Dis 12, 23-35.
15. Jacova J, Kertesz A, Blair M, Fisk JD, Feldman HH (2007) Neuropsychological testing and assessment for dementia. Alzheimers Dement 3, 299-317.
16. Zakzanis KK, Andrikopoulos J, Young DA, Champbell Z, Sethian T (2003) Neuropsychological differentiation of la- teonset schizophrenia and dementia of the Alzheimer's type. Appl Neuropsychol 10, 105-114.
17. Stomrud E, Hansson O, Blennow K, Minthon L, Londos E (2007) Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement Geriatr Cogn Disord 24, 118-124.
18. Mollenhauer B, Bibl M, Wiltfang J, Steinacker P, Ciesielcyk B, Neubert K, Trenkwalder C, Otto M (2006) Total tau protein, phosphorylated tau (181p) protein, beta-amyloid 1-42, and beta-amyloid 1-40 in cerebrospinal fluid of patients with dementia with Lewy bodies. Clin Chem Lab Med 44, 192-195.
19. Wallin AK, Blennow K, Andreasen N, Minthon L (2006) CSF biomarkers for Alzheimer's disease: Levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord 21, 131-138.
20. Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM (2003) Decresed beta-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, 2094-2103.
21. Ivanoiu A, Sindic CJ (2005) Cerebrospinal fluid tau protein and amyloid beta42 in mild cognitive impairment: prediction ofprogression to Alzheimer's disease and correlation with the neuropsychological examination. Neurocase 11, 32-39.
22. Hildebrandt H, Haldenwanger A, Ehling P (2009) False recognition correlates with amyloid-1-42 but not with total tau in cerebrospinal fluid of patients with dementia and mild cognitive impairment. J Alzheimers Dis 16, 157-165.
23. Morris JC, Mohs RC, Rogers H, Fillenbaum G, Heyman A (1988) The consortium to establish a registry for Alzheimer's disease (CERAD). Clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 24, 641652.
24. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fil- lenbaum G, Mellits ED, Clark C, and the CERAD investigators (1989) The consortium to establish a registry for Alzheimer's disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39, 1159-1165.
25. Morris JC, Edland S, Clark C, Galasko D, Koss E, Mohs R, van Belle G, Fillenbaum G, Heyman A (1993) The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 49, 2457-2465.
26. Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fil- lenbaum G, Heyman A (1994) The consortium to establish a registry for Alzheimer's disease (CERAD): A normative study of the neuropsychological battery. Neurology 44, 609-614.
27. Barth S, Schonknecht P, Pantel J, Schroder J (1993) Mild Cognitive Impairment and Alzheimer's Disease: an investigation ofthe CERAD-NP Test battery. Fortschr Neurol Psychiat 73, 1-9.
28. Horn W (1983) Leistungsprufsystem (LPS) Hans Huber Ver- lag, Bern.
29. Lehrl S, Merz J, Burkard G, Fischer B (1991) Mehrfach- Wortschatz-Intelligenztest (MWT-A). Perimed Fachbuchver- lagsgesellschaft, Erlangen.
30. Oswald WD, Fleischmann UM (1986) Nurnberger- Altersinventar NAI, Textkasten und Kurzmanual. Universitat Erlangen-Niirnberg, Erlangen.
31. Wechsler D (1987) WMS-R - Wechsler Memory Scale - Revised. The Psychological Corporation, New York.
32. Beck AT, Hautzinger M, Bailer M, Worall H, Keller F (1985) BDI - Beck-Depressionsinventar. Second edition. Hogrefe, Gottingen.
33. World Health Organization (1992) ICD-10: international statistical classification of diseases and related health problems- based on recommendations of the tenth revision conference, 1989 and adopted by the forty-third World Health Assembly, 10th edn. World Health Organization; Geneva.
34. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders (IV-TR), 4th edn-text revised. Washington, DC.
35. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger- Gateau P, Cummings J, Delacourte A, Galasko, D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquir F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
36. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis ofAlzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
37. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund, L-O, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, De Leon M, Decarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, Van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: report ofthe International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246.
38. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
39. Weimer E & Frohlich L (2005) Labordiagnostik und Liquor- marker bei Alzheimer Krankheit. In: Demenzen. Perspektiven in Praxis undForschung, H. Forstl (ed.), Elsevier, pp. 59-85.
40. K. Blennow (2004) Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1, 213-225.
41. Matthews FE, Stephan BCM, McKeith IG, Bond J, Brayne C, and the Medical Research Council Cognitive Function and Ageing Study (2008) Two-year progression from mild cognitive impairment to dementia: to what extent do different definitions agree? J Am Geriatr Soc 56, 1424-1433.
42. Palmer K, Backman L, Winblad B, Fratiglioni L (2008) Mild cognitive impairment in the general population: occurrence and progression to Alzheimer disease. Am J Geriatr Psychiatry 16, 603-611.
43. Maccioni RB, Lavados M, Guillon M, Mujica C, Bosch R, Farias G, Fuentes P (2006) Anomalously phosphorylated tau and Aft fragments in the CSF correlates with cognitive impairment in MCI subjects. Neurobiol Aging 27, 237-244.
44. Forsberg A, Almkvist O, Engler H, Wall E, Lngstrijm B, Nord- berg A (2010) High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters. Curr AlzRes 7, 56-66.
45. Tombaugh TN (2005) Test-retest reliable coefficients and 5- year change scores for the MMSE and 3MS. Arch Clin Neu- ropsychol 20, 485-503.
46. Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E (2010) Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 67, 217-223.
47. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, De Deyn PP, Galasko D, Hampel H, Hartmann T, Kapaki E, Lannfeld L, Metha PD, Parnetti L, Petzold A, Pirttila T, Saleh L, Skinningsrud A, Swieten JC, Verbeek MM, Wiltfang J, Younkin S, Scheltens P, Blankenstein MA (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 56, 235-240.
48. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, Minthon L, Hansson O (2009) PLoS One 4, e6294.
49. Molinuevo JL, Gomez-Anson B, Monte GC, Bosch B, Sanchez-Valle R, Rami L (2010) Neuropsychological profile of prodromal Alzheimer's disease (Prd-AD) and their radiological correlates. Arch Gerontol Geriatr, in press.
50. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Ja- gust WJ and the Alzheimer's Disease Neuroimaging Initiative (2008) Episodic memory loss is related to hippocampal- mediated beta-amyloid deposition in elderly subjects. Brain 132, 1310-1323.
51. de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Rusinek H, Li J, Tsui W, Saint Louis LA, Clark CM, Tarshish C, Li Y, Lair L, Javier E, Rich K, Lesbre P, Mosconi L, Reisberg B, Sadowski M, DeBernadis JF, Kerkman DJ, Hampel H, Wahlund LO, Davies P (2006) Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging27, 394-401.
52. Petrie EC, Cross DJ, Galasko D Schellenberg GD, Raskind MA, Peskind ER, Minoshima S (2009) Preclinical evidence of Alzheimer changes: convergent cerebrospinal fluid biomarker and fluorodeoxyglucose positron emission tomography findings. Arch Neurol 66, 632-637.